Daniel Meuser
Daniel Meuser (R-PA) sold $250K-$500K of $NVDA (NVIDIA Corporation - Common Stock) on Feb 11, 2025, part of 9 transactions in this filing.
HillSignal flagged 5 timing concerns on this filing — trades that line up closely with related legislative or contract activity.
Price Movement Since Trade
How the largest positions have moved from the trade date to the most recent close.
Showing the 6 largest positions. See every transaction in the table below.
Suspicious Timing Detected
5 flagsDaniel Meuser sold $50K-$100K in $GOOGL on 2025-02-11, 135 days before the STOP CSAM Act of 2025 (S1829) advanced to the Senate Legislative Calendar, a bill that directly increases liability for online platforms.
Daniel Meuser sold $15K-$50K in $AAPL on 2025-02-11, 156 days before the Price Gouging Prevention Act of 2025 (HR4528) was introduced, which could limit corporate profitability for large-cap companies.
Daniel Meuser sold $50K-$100K in $GOOGL on 2025-02-11, 160 days before the AI Accountability and Personal Data Protection Act (S2367) was introduced, which creates a Federal tort for data exploitation.
These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
| Type | Ticker | Asset | Amount | Trade Price | Current | Change | Date |
|---|---|---|---|---|---|---|---|
| PARTIAL SELL | $NVDA | NVIDIA Corporation - Common Stock | $250K-$500K | $132.80 | — | — | Feb 11, 2025 |
| SELL | $GOOGL | Alphabet Inc. - Class A Common Stock | $50K-$100K | $185.32 | — | — | Feb 11, 2025 |
| SELL | $AAPL | Apple Inc. - Common Stock | $15K-$50K | $232.62 | — | — | Feb 11, 2025 |
| SELL | $QCOM | QUALCOMM Incorporated - Common Stock | $15K-$50K | $171.99 | — | — | Feb 11, 2025 |
| SELL | $V | Visa Inc. | $15K-$50K | $350.72 | — | — | Feb 11, 2025 |
| SELL | $AMGN | Amgen Inc. - Common Stock | $1K-$15K | $296.66 | — | — | Feb 11, 2025 |
| SELL | $APTV | Aptiv PLC Ordinary Shares | $1K-$15K | $64.66 | — | — | Feb 11, 2025 |
| SELL | $MSFT | Microsoft Corporation - Common Stock | $1K-$15K | $411.44 | — | — | Feb 11, 2025 |
| SELL | $MDLZ | Mondelez International, Inc. - Class A Common Stock | $1K-$15K | $60.45 | — | — | Feb 11, 2025 |
Connected Legislative Activity
10 signalsThese bills and contracts share tickers or sectors with this filing's trades.
Treat and Reduce Obesity Act of 2025
The Treat and Reduce Obesity Act of 2025 would mandate Medicare Part D coverage of GLP-1 obesity drugs, unlocking a massive new payer market of ~27 million beneficiaries. $NVO and $LLY are the two direct beneficiaries. The bill is in early-stage committee referral with 22 bipartisan cosponsors; no companion bill has passed the House yet. Real market data shows $NVO gaining 15.56% over 30 days vs $LLY's +0.7%, suggesting the market may be overweighting Novo's near-term Medicare exposure given its larger U.S. obesity market share.
Taiwan Non-Discrimination Act of 2025
HR910 is a diplomatic bill requiring the U.S. Treasury to advocate for Taiwan's equitable treatment at the IMF. It authorizes zero funding, imposes no mandatory regulations on U.S. companies, and has no direct market impact on any publicly traded entity. The bill is procedural in nature—directing U.S. votes within an international institution—and carries no binding economic mechanisms for U.S. firms.
MAPWaters Act of 2025
The MAPWaters Act, with a companion bill already signed into law (HR187 → PL 119-62), mandates federal agencies to standardize geospatial waterway data. Trimble ($TRMB) is the primary pure-play beneficiary. The stock is at $66.84, near the bottom of its 52-week range ($62–$87.5), offering a potential entry point if procurement contracts materialize. No funding is authorized directly, so revenue depends on agency procurement budgets.
Small Biotech Innovation Act
The Small Biotech Innovation Act (HR3731) is an early-stage bill that would exempt R&D-intensive small biotech manufacturers (≤5 qualifying drugs) from Medicare drug price negotiations starting in 2029. The bill is in committee with no floor action, and no market reaction is evident from provided data. The legislative path is long and uncertain — this is a structural watch item, not a trading catalyst.
Price Gouging Prevention Act of 2025
The Price Gouging Prevention Act of 2025 (HR4528) is an early-stage House bill capping corporate margins during 'exceptional market shocks'. Currently referred to committee with zero appropriations, the bill poses a structural long-term regulatory risk to all large-cap companies with pricing flexibility, particularly retailers ($WMT, $AMZN) and integrated energy ($XOM, $CVX). Near-term market impact is low given early legislative stage, but the bill's breadth — covering all goods and services — represents a significant expansion of FTC authority if it advances.
AI Accountability and Personal Data Protection Act
S.2367 introduces a broad federal tort for personal data exploitation without express consent, directly targeting the data practices underlying AI training and advertising at META, GOOGL, AMZN, MSFT, and CRM. The bill is early-stage (introduced July 2025, referred to Judiciary Committee), but its language is aggressive and unambiguous. Current market prices show a sharp 1-day drop for META (-8.72% 7-day) and GOOGL at an all-time high of $373.96 — divergence suggests GOOGL's run is driven by other factors, not immunity from this risk.
Access Technology Affordability Act of 2025
S. 1918 is an early-stage, low-probability bill proposing a refundable tax credit for blind individuals purchasing access technology. It creates no direct revenue stream for any public company and has negligible near-term market impact.
Small Nonprofit Retirement Security Act of 2025
HR4548 opens the tax-exempt small employer market (1.3M 501(c) organizations) to retirement plan subsidies for the first time, creating a new customer acquisition opportunity for payroll and retirement administration providers ADP and PAYX. The bill is in early legislative stages with bipartisan sponsorship.
Blue Shield Privacy Act of 2025
The Blue Shield Privacy Act of 2025 (HR4828) is an early-stage House bill that expands the definition of 'restricted personal information' under federal criminal law to include biometric data, GPS coordinates, license plates, and workplace/school addresses. At referral to the House Judiciary Committee only, with 7 cosponsors and no markup or hearings yet, the bill has no near-term market impact. Real market data show GOOGL at $368.29 (up 6.94% over 7 days, up 28.07% over 30 days), META at $600.42 (down 11.05% over 7 days), AMZN at $258.48 (down 2.09% over 7 days), and MSFT at $400.59 (down 5.66% over 7 days) — these price movements are driven by other factors, not this procedural bill.
STOP CSAM Act of 2025
The STOP CSAM Act (S.1829) has advanced to the Senate calendar, increasing passage probability. The bill mandates elevated content moderation and reporting requirements for major tech and telecom companies, directly increasing compliance costs. Affected tickers include $META, $GOOGL, $MSFT, $AMZN, $VZ, $T, and $TWLO. Market data shows strong recent rallies in tech stocks ($GOOGL +27.95%, $META +24.75%, $AMZN +30.9% over 30 days), creating potential downside risk if compliance cost headwinds materialize.
Other Filings by Daniel Meuser
Free — no credit card
Get the next Meuser trade the day it's disclosed
HillSignal tracks every Congressional stock filing and federal contract, scores its market impact with AI, and emails you the ones that matter — before they hit the news.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.